Shufeng Xingbi Therapy Modulates Immunity and Gut Flora in AR Rats

Study Background and Research Question

Allergic rhinitis (AR) is a chronic, non-infectious inflammatory disease of the nasal mucosa characterized by symptoms such as sneezing, nasal itching, congestion, and watery discharge. Affecting over 10% of the global population, AR is primarily mediated by IgE and the imbalance of T helper cell subsets (Th1/Th2) following allergen exposure. Modern pharmacological treatments—glucocorticoids, antihistamines, leukotriene receptor antagonists, and decongestants—offer symptomatic relief but may cause adverse effects, particularly in pediatric populations. Recent advances have drawn attention to the "hygiene hypothesis," positing that early-life environmental and microbial exposures shape immune tolerance and susceptibility to allergic diseases. Traditional Chinese Medicine (TCM) has shown promise in AR management, with Shufeng Xingbi Therapy (SFXBT)—a regimen combining oral herbal administration and nasal gel drops—emerging from decades of clinical insights. However, the mechanistic underpinnings of SFXBT, particularly regarding gut mucosal immunity and microbiota, remained unexplored. The reference study (Yan et al., 2025) addressed this gap by investigating how SFXBT modulates Th1/Th2 balance and alters intestinal flora in an OVA-induced AR rat model.

Key Innovation from the Reference Study

The primary innovation of this research lies in its integrative approach: it combines immunological profiling (Th1/Th2 markers, cytokines, transcription factors) with high-resolution analysis of the intestinal microbiome and metabolic readouts (short-chain fatty acids, SCFAs). By dissecting both systemic and mucosal mechanisms, the study provides compelling evidence that SFXBT not only attenuates nasal inflammation but also orchestrates gut microbial restructuring. This dual focus advances our understanding of the gut-immune axis in allergic airway disease and positions SFXBT as a potential model for integrative anti-allergy interventions.

Methods and Experimental Design Insights

The study employed thirty-two male Sprague-Dawley rats, randomly allocated into four groups:

• Control group (no AR induction)
• OVA group (AR model, no intervention)
• Antibiotic + SFXBT group
• Acetic acid + SFXBT group

AR was induced using ovalbumin (OVA) sensitization, a well-established protocol for mimicking human allergic airway responses. SFXBT was administered both orally and intranasally. To probe the gut-immune interface, some rats received antibiotics or acetic acid to modulate the intestinal environment prior to SFXBT treatment. Key measurements included:

• Behavioral scoring for AR symptoms (sneezing, scratching, discharge)
• Histopathological assessment of nasal mucosa (H&E staining)
• 16S rDNA sequencing for colonic microbiota analysis
• ELISA quantification of serum IgE, IL-4, and SCFAs
• RT-qPCR for mRNA expression of STAT5, STAT6, and GATA3 in nasal tissue
• Western blotting for protein levels of IL-4, STAT5, STAT6, and GATA3

This comprehensive design allowed the authors to link clinical, molecular, and microbial endpoints, establishing a multidimensional map of therapeutic action.

Protocol Parameters

• OVA-induced AR modeling: Intraperitoneal sensitization with OVA and subsequent nasal challenge to induce allergic rhinitis symptoms.
• SFXBT intervention: Oral administration combined with nasal drop application, reflecting clinical practice in TCM.
• Antibiotic pretreatment: Utilized to disrupt gut microbiota before SFXBT, thereby clarifying the role of microbial modulation.
• Microbiome profiling: 16S rDNA sequencing of colonic content for taxonomic and abundance analysis of key bacterial groups.
• Immunological analysis: RT-qPCR and Western blotting for Th2-associated transcription factors and cytokines in nasal tissue, with ELISA for systemic markers.

Core Findings and Why They Matter

The study found that, compared to the OVA-only group, both the antibiotic + SFXBT and acetic acid + SFXBT groups exhibited significantly reduced AR behavioral scores and alleviated nasal mucosal pathology (Yan et al., 2025). Microbiota analysis revealed a marked increase in the relative abundance of Firmicutes and genera such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella, with a concomitant decrease in Bacteroidetes. This shift was associated with elevated levels of SCFAs, known to exert anti-inflammatory effects through regulatory T cell pathways. Immunologically, SFXBT treatment led to reductions in serum IgE and IL-4—hallmarks of Th2-skewed allergic responses. Both gene and protein expression of STAT5, STAT6, and GATA3 (critical regulators of Th2 differentiation and cytokine signaling) were significantly downregulated in nasal mucosa. Together, these data support the hypothesis that SFXBT restores Th1/Th2 equilibrium and mitigates allergic inflammation via gut microbiota modulation. These findings are significant for several reasons:

• They validate the gut-immune axis as a mechanistic target in AR.
• They provide experimental support for integrating traditional and modern therapeutic strategies.
• They highlight the importance of microbiome composition and metabolites (SCFAs) in controlling systemic allergic responses.

Comparison with Existing Internal Articles

Several internal articles expand on the role of microbiota and immune modulation in disease models:

• "Vancomycin as a Precision Modulator of Gut-Immune Interactions" details how the glycopeptide antibiotic Vancomycin can selectively deplete Gram-positive bacteria, enabling studies on the interplay between microbiota and immune responses in models of MRSA and Clostridium difficile infection. The approach parallels the reference study’s use of antibiotics to probe gut-immune mechanisms in allergy.
• "Vancomycin in Immune-Microbiome Research: Beyond Cell Wall Inhibition" reviews Vancomycin’s effects on peptidoglycan precursor binding and downstream immune modulation, reinforcing the concept that microbiome-targeting agents can indirectly influence inflammatory pathways relevant to AR and other immune-mediated diseases.
• "Vancomycin: Glycopeptide Antibiotic for MRSA & Resistance Studies" highlights standardized protocols using high-purity Vancomycin for investigating bacterial resistance and host-pathogen interactions, which may inform similar experimental setups in allergy-microbiome research.

While the reference study focuses on a TCM-based intervention, the use of antibiotics (and specifically glycopeptide antibiotics like Vancomycin) as tools to manipulate the gut microbiota provides a methodological bridge between traditional and contemporary research paradigms.

Limitations and Transferability

Despite its robust design, several limitations warrant consideration. The study’s findings are based on a rat model and may not fully translate to human AR, given interspecies differences in immune regulation and microbiota composition. The use of antibiotics and acetic acid to manipulate the gut environment, while informative, introduces variables that may not mirror clinical scenarios. Additionally, the exact bioactive constituents and pharmacokinetics of SFXBT remain to be elucidated. Transferability to broader research contexts should be approached cautiously. Nonetheless, the study’s workflow—integrating immunological, microbial, and metabolic readouts—can inform future investigations into gut-immune interactions for other immune-mediated or infectious diseases, provided appropriate controls and validation steps are observed.

Research Support Resources

For researchers aiming to dissect gut microbiota-immune interplay in rodent or in vitro models, the use of targeted antibiotics remains a foundational tool. Vancomycin (SKU C6417) from APExBIO, a glycopeptide antibiotic with well-characterized inhibition of bacterial cell wall synthesis via D-Ala-D-Ala peptidoglycan precursor binding, can be leveraged to selectively modulate Gram-positive bacterial populations in the gut. Its high purity and validated analytical profile are suitable for controlled studies in antibacterial agent and microbiome research, including work on methicillin-resistant Staphylococcus aureus and Clostridium difficile infection. For optimal results, researchers should consider Vancomycin’s solubility in DMSO and follow recommended storage guidelines. This approach enables reproducible manipulation of the microbiome and supports advanced modeling of immune-microbiota dynamics akin to those described in the reference study.